Compare Kinder Morgan Inc (KMI) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kinder Morgan Inc vs Merck & Co., Inc. — how do they compare? Kinder Morgan Inc trades at $32.21 (market cap $72.48B), while Merck & Co., Inc. trades at $125.97 (market cap $307.25B). The key difference: Merck & Co., Inc. is far larger — about 4.2× Kinder Morgan Inc's market cap, and Kinder Morgan Inc pays the higher dividend (3.61%). Which is the better fit depends on your goals.
| KMI | MRK | |
|---|---|---|
Market Cap | $72.48B | $307.25B |
Sector | Energy | Health |
52-Week High | $34.31 | $129.52 |
52-Week Low | $25.84 | $77.60 |
Enterprise Value | $104.36B | $350.66B |
Dividend Yield | 3.61% | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kinder Morgan (KMI) trades at $32.71, up 1.27% with neutral technical signals. The company shows strong fundamentals with revenue growth from $15.1B in 2024 to $16.9B in 2025 and net income margin improving to 18.04%. Recent Q1 2026 earnings beat expectations with $0.48 EPS versus $0.40 expected. KMI maintains a $10.1B project backlog focused on natural gas infrastructure, supporting future growth. Analyst sentiment is mixed with 47% buy ratings but technical indicators show neutral momentum near key support at $32.
KMI presents a balanced opportunity with stable cash flows from fee-based contracts and dividend yield near 4%. Upside potential exists from LNG export growth and power demand, though valuation appears fair at P/E of 21.7. Key risks include commodity price exposure and high debt levels at $29.7B long-term. The stock offers income stability but limited near-term catalysts given neutral technical positioning.
Merck (MRK) trades at $124.30, down 2.51% over the past day, amid a generally bullish technical setup with moving averages signaling strength. The company reported solid earnings beats in recent quarters, including Q1 2026, with revenue reaching $65.01B in 2025 and net income of $18.25B. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives. Analyst sentiment remains strongly positive, with a consensus price target of $137.30 and 68% buy ratings.
The outlook for MRK is favorable, supported by robust profitability margins, strategic acquisitions, and strong institutional interest. Key risks include integration challenges from recent M&A, patent expirations, and regulatory pressures. The stock's current valuation at a P/E of 35.04 may limit near-term upside, but long-term growth drivers in pharmaceuticals provide a solid foundation for investor confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kinder Morgan Inc
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
Read more on KMI →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
